Who's minding the data? Data Monitoring committees in clinical cancer trials

Sociology of Health and Illness

Volumn 31, Issue 3, 2009, Pages 325-342

  Keating, Peter ^a   Cambrosio, Alberto ^b  

^a UNIVERSITY OF QUEBEC   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Biomedicine; Clinical trials; Committees; Data monitoring; Objectivity; Regulation

Indexed keywords

ARTICLE; BIOMETRY; CLINICAL TRIAL; HISTORY; HUMAN; INFORMATION SYSTEM; MEDICAL RESEARCH; NEOPLASM; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; STATISTICS;

BIOMEDICAL RESEARCH; BIOMETRY; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; HISTORY, 20TH CENTURY; HUMANS; INFORMATION MANAGEMENT; NEOPLASMS;

EID: 63849221533     PISSN: 01419889     EISSN: 14679566     Source Type: Journal    
DOI: 10.1111/j.1467-9566.2008.01136.x     Document Type: Article

References (43)

1. Anonymous 1993) Panel discussion: scientific issues in data monitoring, Statistics in Medicine, 12, 583 600.
2. Armitage, P. (2001) Theory and practice in medical statistics, Medical Statistics, 20, 2537 48.
3. Armitage, P., McPherson, C.K. Rowe, B.C. (1969) Repeated analysis of clinical trial data, Journal of the Royal Statistical Society, Series A, 132, 235 44.
4. Boltanski, L. Thévenot, L. (1999) The sociology of critical capacity, European Journal of Social Theory, 2, 359 77.
5. Cambrosio, A., Keating, P., Schlich, T. Weisz, G. (2006) Regulatory objectivity and the generation and management of evidence in medicine, Social Science & Medicine, 63, 189 199.
6. Cambrosio, A., Keating, P. Bourret, P. (2007) Objectivité régulatoire et systèmes de preuves en médecine: Le cas de la cancérologie. In Tournay, V. (ed.) La gouvernance des innovations biomédicales. Paris : Presses Universitaires de France.
7. Canner, P.L. (1977) Monitoring treatment differences in long-term clinical trials, Biometrics, 33, 603 15.
8. Daston, L. (1992) Objectivity and the escape from perspective, Social Studies of Science, 22, 597 618.
9. Daston, L. Galison, P. (1992) The image of objectivity, Representations, 40, 81 128.
10. Daston, L. Galison, P. (2007) Objectivity. New York : Zone Books.
11. Ellenberg, S.S. George, S.L. (2004) Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?, Statistics in Medicine, 23, 1503 05.
12. Ellenberg, S., Geller, N., Simon, R. Yusuf, S. (1993) Preface, Statistics in Medicine, 12, 451.
13. Ellenberg, S., Fleming, T. DeMets, D.L. (2002) Data Monitoring Committees in Clinical Trials. A Practical Perspective. Hoboken, N.J John Wiley.
14. EMEA 2005) European Medicine Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), Guideline on Data Monitoring Committees (London, 27 July 2005) http://www.emea.eu.int/pdfs/human/ewp/587203en.pdf
15. Epstein, S. (2007) Inclusion: the Politics of Difference in Medical Research. Chicago : University of Chicago Press.
16. FDA 2001a) Food and Drug Administration, Guidance for Clinical Trial Sponsors. On the Establishment and Operation of Clinical Trial Data Monitoring Committees. Draft Guidance http://www.fda.gov/Cber/gdlns/clindatmon.pdf
17. FDA 2001b) FDA Guidance on Clinical Trial Data Monitoring Committees (DMCs). Open Public Meeting, FDA Guidance on Clinical Trial Data Monitoring Committees (DMCs). Tuesday, November 27, 2001. Hyatt Regency Bethesda, Rockville (MD)
18. part 1: http://www.fda.gov/cber/minutes/clinmon1101p1.htm
19. part 2: http://www.fda.gov/cber/minutes/clinmon1101p2.htm
20. FDA. (2006) Food and Drug Administration, Guidance for Clinical Trial Sponsors. Establishment and Operation of Clinical Trial Data Monitoring Committees http://www.fda.gov/CBER/gdlns/clintrialdmc.pdf
21. Fisher, M., Roeker, E.B. DeMets, D.L. (2001) The role of an independent statistical analysis center in the industry-modified National Institutes of Health model, Drug Information Journal, 35, 115 29.
22. Grant, A.M., Altman, D.G., Babiker, A.B., Campbell, M.K., Clemens, F.J., Darbyshire, J.H., et al 2005) Issues in data monitoring and interim analysis of trials, Health Technology Assessment, 9, 7, xiv + 238 pp.
23. Green, S.J., Fleming, T.R. O'Fallon, J.R. (1987) Policies for study monitoring and interim reporting of results, Journal of Clinical Oncology, 5, 1477 84.
24. Green, S., Benedetti, J. Crowley, J. (1997) Clinical Trials in Oncology. New York : Chapman and Hall.
25. Greenberg Report 1988) Organization, review, and administration of cooperative studies: a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967, Controlled Clinical Trials, 9, 137 48.
26. Harrington, D., Crowley, J., George, S.L., Pajak, T., Redmond, C. Wieand S. (1994) The case against independent monitoring committees, Statistics in Medicine, 13, 1411 14.
27. Haybittle, J.L. (1971) Repeated assessment of results in clinical trials of cancer treatment, British Journal of Radiology, 44, 793 7.
28. Keating, P. Cambrosio, A. (2007) Cancer clinical trials: the emergence and development of a new style of practice, Bulletin of the History of Medicine, 81, 197 223.
29. Kerr, D., McBride, R. Shemanski, L. (2004) Data monitoring committees in practice. Tips on using DMCs to improve trial efficiency and safety, Applied Clinical Trials http://www.actmagazine.com/appliedclinicaltrials/article/ articleDetail.jsp?id=87247.
30. Kiri, A., Tonascia, S. Meinert, C.L. (2004) Treatment effects monitoring committees and early stopping in large clinical trials, Clinical Trials, 1, 40 7.
31. Lynch, M.E. (1982) Technical work and critical inquiry: investigations in a scientific laboratory, Social Studies of Science, 12, 499 533.
32. Marks, H. (1998) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990. Cambridge : Cambridge University Press.
33. McPherson, K. (1974) Statistics: the problem of examining accumulating data more than once, New England Journal of Medicine, 290, 501 02.
34. Meinert, C.L. (1998a) Rejoinder, Controlled Clinical Trials, 19, 539 43.
35. Meinert, C.L. (1998b) Masked monitoring in clinical trials. Blind stupidity?, New England Journal of Medicine, 338, 1381 2.
36. Pocock, S.J. (1977) Group sequential methods in the design and analysis of clinical trials, Biometrika, 64, 191 9.
37. Rochold, F.W. Enas, G.G. (1993) Data monitoring and interim analysis in the pharmaceutical industry: ethical and logistical considerations, Statistics in Medicine, 12, 471 9.
38. Simon, R. (1993) Remarks quoted in 'Discussion', Statistics in Medicine, 12, 521 5.
39. Slutsky, A.S. Lavery, J.V. (2004) Data safety and monitoring boards, New England Journal of Medicine, 350, 1143.
40. Smith, M.A., Ungerleider, R.S., Korn, E.L., Rubensteib, L. Simon, R. (1997) Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute, Journal of Clinical Oncology, 14, 2736 43.
41. Sydes, M.R., Altman, D.G., Babiker, A.B., Parmar, M.K.B., Spiegelhalter, D.J. the DAMOCLES Group 2004) Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study, Clinical Trials, 1, 48 59.
42. Sylvester, R. (2002) Comment Number EC-7 on the Draft Guidance: Clinical Trial Sponsors on the Establishment & Operation of Clinical Trial DMCs (Docket: 01D-0489) http://www.fda.gov/ohrms/dockets/dailys/02/Feb02/022702/01D- 0489-EC-7.html
43. Vastag, B. (2006) New clinical trials policy at FDA, Nature Biotechnology, 24, 1043.